DDD Partners LLC Has $15.68 Million Stock Holdings in Elanco Animal Health Incorporated (NYSE:ELAN)

DDD Partners LLC raised its position in Elanco Animal Health Incorporated (NYSE:ELAN - Free Report) by 202.7% in the 1st quarter, according to its most recent filing with the SEC. The firm owned 1,492,992 shares of the company's stock after acquiring an additional 999,716 shares during the period. Elanco Animal Health makes up 1.9% of DDD Partners LLC's investment portfolio, making the stock its 25th largest holding. DDD Partners LLC owned 0.30% of Elanco Animal Health worth $15,676,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently made changes to their positions in the stock. Victory Capital Management Inc. lifted its stake in shares of Elanco Animal Health by 138.8% in the first quarter. Victory Capital Management Inc. now owns 271,338 shares of the company's stock valued at $2,849,000 after purchasing an additional 157,708 shares during the period. New York State Common Retirement Fund increased its holdings in Elanco Animal Health by 1.5% during the 1st quarter. New York State Common Retirement Fund now owns 280,065 shares of the company's stock valued at $2,941,000 after acquiring an additional 4,209 shares in the last quarter. Xponance Inc. increased its holdings in Elanco Animal Health by 8.4% during the 1st quarter. Xponance Inc. now owns 24,415 shares of the company's stock valued at $256,000 after acquiring an additional 1,891 shares in the last quarter. Country Club Bank increased its holdings in Elanco Animal Health by 112.5% during the 1st quarter. Country Club Bank now owns 280,716 shares of the company's stock valued at $2,922,000 after acquiring an additional 148,643 shares in the last quarter. Finally, Allworth Financial LP grew its holdings in shares of Elanco Animal Health by 791.7% during the first quarter. Allworth Financial LP now owns 2,354 shares of the company's stock worth $25,000 after buying an additional 2,090 shares in the last quarter. Institutional investors and hedge funds own 97.48% of the company's stock.

Wall Street Analysts Forecast Growth

Several research firms recently issued reports on ELAN. William Blair raised shares of Elanco Animal Health from a "market perform" rating to an "outperform" rating in a research report on Thursday, June 26th. Leerink Partnrs raised shares of Elanco Animal Health from a "hold" rating to a "strong-buy" rating in a research report on Thursday. Wall Street Zen raised shares of Elanco Animal Health from a "hold" rating to a "buy" rating in a research report on Saturday, July 5th. Stifel Nicolaus lifted their price target on shares of Elanco Animal Health from $16.00 to $17.00 and gave the company a "buy" rating in a research report on Wednesday, July 2nd. Finally, Leerink Partners raised shares of Elanco Animal Health from a "market perform" rating to an "outperform" rating and set a $18.00 target price on the stock in a research report on Thursday. Two analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $16.00.

Elanco Animal Health Stock Down 1.2%

Shares of ELAN traded down $0.18 during trading hours on Friday, reaching $14.78. The company's stock had a trading volume of 3,045,323 shares, compared to its average volume of 5,032,333. The firm has a market cap of $7.34 billion, a price-to-earnings ratio of 19.97, a P/E/G ratio of 2.92 and a beta of 1.67. Elanco Animal Health Incorporated has a 1-year low of $8.02 and a 1-year high of $15.78. The company has a quick ratio of 1.46, a current ratio of 2.71 and a debt-to-equity ratio of 0.68. The company has a 50 day moving average of $13.82 and a two-hundred day moving average of $11.79.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last released its quarterly earnings data on Wednesday, May 7th. The company reported $0.37 EPS for the quarter, topping analysts' consensus estimates of $0.31 by $0.06. Elanco Animal Health had a return on equity of 7.54% and a net margin of 8.43%. The firm had revenue of $1.19 billion for the quarter, compared to the consensus estimate of $1.17 billion. During the same quarter in the prior year, the company posted $0.34 earnings per share. The firm's revenue was down 1.0% on a year-over-year basis. As a group, research analysts predict that Elanco Animal Health Incorporated will post 0.91 EPS for the current fiscal year.

About Elanco Animal Health

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.